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Abstract
Standard treatment for the majority of malignant brain tumours consists of surgery and radiotherapy. This treatment has late morbidity which is accentuated in the very young child. As part of a strategy to improve quality of life and overall survival of young children with brain tumours, members of the United Kingdom Children's Cancer Study Group (UKCCSG) have piloted an intensive chemotherapy regimen which aims to avoid or delay radiotherapy following surgery. Twenty eight children with a variety of malignant brain tumours have received the regimen, which contains carboplatin, vincristine, cyclophosphamide, methotrexate, and cisplatin. The treatment is toxic, resulting in one death from infection. The bulk of the toxicity was associated with the administration of carboplatin. All but three children eventually required adjuvant radiotherapy and this was given between 1.5 and 27 months from diagnosis (median delay to radiotherapy, 12 months). Using this treatment regimen, overall survival at four years is 35% (confidence intervals 10% to 60%). While there is no evidence from this study that radiotherapy can be abandoned in the management ofmalignant brain tumours, its introduction may be delayed using suitable chemotherapy, thus allowing time for further CNS development. This treatment strategy has been taken forward as an international clinical trial run through the International Society for Paediatric Oncology, but using a smaller dose of carboplatin to reduce toxicity. ( Following surgery, patients were staged to define the extent of the residual tumour. This comprised either computed tomographic (CT) scanning of the head and myelography, or nuclear magnetic resonance (NMR) imaging of the head and spine. The chemotherapy schedule was designed to incorporate agents of proven activity against a range of CNS tumour types. The drugs were scheduled so that myelosuppressive agents were alternated with less myelosuppressive agents, leading to the design of repeated pulses of chemotherapy at 14 day intervals (table) . This schedule results in the least myelosuppressive chemotherapy at a time of neutropenia and thrombocytopenia. Treatment was to be given on time unless life threatening complications supervened. Centres were encouraged to treat children on the chemotherapy schedule for a period of one year unless relapse or progression of the tumour occurred. Radiotherapy was recommended either at the time of relapse or in the case of biopsy proven residual disease at the end of the chemotherapy schedule. Local irradiation comprised a total dose of 50 Gy. Craniospinal radiation was 25 Gy to children under 3 years and 35 Gy to children over the age of 3, given for tumours that are known to metastasise within the neuroaxis.
All UKCCSG centres were surveyed and patients treated on the protocol were notified to one of the authors. In view of the intensity of the protocol, the first 62 cycles of chemotherapy were evaluated for the complications of treatment and duration of hospital stay. Centres were visited by one of the authors, the notes inspected, and toxicity graded by WHO criteria.
Children treated on the study were followed to time of radiotherapy, relapse or death 0-6 7-12 13-18 [19] [20] [21] [22] [23] [24] 25-30 31-36 37-42 43-48 49-54 through the data monitoring service of the UKCCSG.
Results
Twenty eight children were treated on this study at a median age of 14-5 months (range: 1 to 33 months). The children presented the spectrum of malignant tumours seen in the very young child. These comprised 16 primitive neuroectodermal tumours (including medulloblastoma), five ependymomas, and seven others. In the latter group there were three children with choroid plexus carcinoma, three with malignant astrocytoma, and one meningeal sarcoma. There was an unusual distribution of primary sites in patients with a diagnosis of primitive neuroectodermal tumour (PNET), 39% of tumours occurring at sites outside the posterior fossa. The majority of children (75%) had an incomplete surgical resection (that is, residual abnormality on postoperative imaging suggestive of residual disease), three of whom received only biopsy. These were two patients with a PNET and one with glioblastoma. Imaging of the craniospinal axis revealed four patients with coexisting metastatic disease within the neuraxis.
Each full cycle of chemotherapy was projected to take 56 days, with 10 of these days spent in hospital for the chemotherapy to be given. The median time to administer cycles 1-6 was 60, 60, 66, 55, 62, and 64 days respectively. Most treatment cycles resulted in additional hospital admissions for complications of the chemotherapy. The median time spent in hospital for treatment related toxicity was 14 days and was largely attributable to infection (94 episodes); 370/o of infective episodes were due to a febrile neutropenia in which no organism was identified, and in 21% an organism was cultured from serial blood samples. Three episodes were associated with severe sepsis, two with septic shock, and there was one infection related toxic death. Of particular note was the fact that the majority of infections were temporally related to the carboplatin induced neutropenia at the beginning of each cycle. Additionally, 14 treatment cycles were associated with significant haemorrhage, five with WHO grade 3-4 neurotoxicity, and 11 with WHO grade 3-4 pulmonary toxicity. Interestingly, eight episodes of pulmonary toxicity occurred in five patients with a pre-existing bulbar palsy. Of the 28 patients treated on the study, six died before radiotherapy could be given. These included the patient who died from sepsis and was shown to have persistent tumour at necropsy. Irradiation was not given to the remaining five patients either because of young age (one patient) or rapid progression of disease. Nineteen patients were eventually irradiated, six to the original site of the primary tumour and 13 with full craniospinal irradiation. The median time interval from initial surgery to radiotherapy was 12 months (range 1-5 to 27 months), resulting in a substantial shift in the distribution of age at irradiation ( fig  1) . This is further illustrated by the difference in the event-free and crude survival of this USA, where young patients were found to die method). (B) OveraUl survivalfor all patients in the study, early and without effective treatment. 16 with 95% confidence intervals (Kaplan-Meier method).
In an attempt to improve the dismal prognosis for these children, various national groups group of patients (fig 2A,B) . The most infor-are attempting to use chemotherapy either to mative curve is the crude survival (2B), as the delay or prevent CNS irradiation. One chaltreatment strategy anticipates that a sizeable lenge is to define a chemotherapy schedule proportion of patients will relapse or progress, with activity against a broad range of tumours. but may be rescued by delayed radiotherapy. The majority of treatment regimens include Fourteen patients (50%) are still alive at a platinum analogues, cyclophosphamide, and median follow up of 35 months (range 26 to vincristine, which have been shown to have 62), of whom three are in continuous complete activity against astrocytomas, PNETs, and remission without ever being irradiated at 27, ependymomas.17-20 A high dose infusion of 31, and 49 months from diagnosis (two with methotrexate was included in this schedule to malignant astrocytoma and one PNET). improve its CNS penetration2l and resulted in Overall survival is 35% at 4 years, but has wide the design of a novel schedule which rapidly confidence intervals (10% to 60%). alternated myelosupressive drugs (carboplatin, One group that warrants separate analysis cyclophosphamide) with less myelosuppressive comprises the patients with PNET. These drugs (methotrexate, cisplatin). The rationale patients require total CNS irradiation to con-of the schedule was to expose the tumour to trol disease and are a group which would multiple agents with different modes of action derive maximum benefit from an effective in an attempt to reduce the emergence of drug chemotherapy strategy. This group includes resistance. Such a regimen was recognised to patients with medulloblastoma (10 patients) be potentially toxic and so the main purpose of and six others with supratentorial primary this study was to assess the feasibility of the tumours. Three of these patients were identi-approach. As such, no attempt was made to fied as having CNS metastatic disease at pre-ascertain the number of children within the sentation. In 14 of these patients (88%) the United Kingdom eligible for study but treated tumours either progressed or recurred, result-by other methods. The chemotherapy proved ing in 12 patients being irradiated at between to be toxic, resulting in substantial need for four and 23 months from diagnosis (median hospital admission for infection and haemordelay; 11 months). Eight patients remain alive, rhage, as well as one toxic death. Much of the of whom one is alive at 31 months without ever toxicity was related to the carboplatin, with having been irradiated. more acute toxicity occurring during the first period of neutropenia and thrombocytopenia of each treatment cycle. Additional problems Discussion included the development of a severe respiraCentral nervous system tumours account for tory illnesses in a small number of patients. between 20% and 25% of all childhood cancer Several drugs including methotrexate can and are thus the second most frequent malig-cause or contribute to lung injury22 but this did nancy of childhood.2 For the majority of not appear to be the case in this schedule, children, irradiation of the primary tumour has as it was clear that there was an excess of respiratory illness in patients with a bulbar palsy. It was felt that the recurrent respiratory distress was contributed to by repeated aspiration. Similarly, it was clear that neurotoxicity occurred because of shunt malfunction or progressive tumour, rather than drug related events. In general it was felt that the chemotherapy schedule was feasible, but because of the incidence of life threatening infection and haemorrhage following carboplatin it was recommended that future studies be undertaken with a reduced dose of this drug. These recommendations have been incorporated into an international multicentre study of the chemotherapy schedule for treatment of very young children with brain tumours administered by the International Society for Paediatric Oncology (SIOP) and the UKCCSG. The study opened in 1992 and is still recruiting patients.
The pilot patients have been monitored continuously to indicate any problems that are likely to emerge in the SIOP study. The small size of the pilot study makes it impossible to judge the efficacy of the treatment regimen. However, a few conclusions can be drawn which may aid in the development of future treatment approaches. Firstly, it is clear that it is possible to delay CNS radiotherapy for a substantial number of patients. The pilot study did not recommend routine irradiation at the end of chemotherapy unless there was histologically proven residual disease. This policy resulted in a median delay of 12 months from diagnosis to radiotherapy, allowing further CNS maturation to take place. At one extreme of outcome this has resulted in three patients who have not yet been irradiated, including one with a malignant astrocytoma in whom the tumour was only biopsied, and one with medulloblastoma who had residual disease at the end of treatment. However, the majority of patients eventually required irradiation to control CNS disease, suggesting that this chemotherapy schedule may be incapable of eradicating residual tumour. The majority of recent clinical protocols treating very young children with brain tumours take this view and incorporate guidelines for radiotherapy, at either a specified age or a specified duration of treatment.8 Less intensive chemotherapy is usually continued until radiotherapy is given. The current SIOP/UKCCSG study has continued with the philosophy developed in the pilot study and does not recommend routine irradiation at the end of chemotherapy in patients with no evidence of active tumour. This may be important, as the study enrols patients with a wide variety of primary brain tumours and in a larger cohort of patients it may be possible to identify a group who will benefit from chemotherapy alone. This issue is being closely monitored.
Various small single institution studies have suggested a role for preirradiation chemotherapy in the management of the young child. 23 24 These studies have not only been valuable in indicating the validity of the treatment strategy but have shown that a wide range of paediatric brain tumours respond to chemotherapy. For example, the largest and perhaps most successful study of young children treated with pulsed chemotherapy and delayed irradiation has been run through the Paediatric Oncology Group (POG). This was a large multicentre study which enrolled 206 patients and produced an overall two year survival of 53%. 10 The study has also provided the best evidence to date that ependymomas are chemosensitive, recording a response rate of 48% to two cycles of vincristine and cyclophosphamide. Our pilot study indicates a similar two year survival of 58%, but with wide confidence intervals and with evidence of continuing relapse. It will be necessary to await the outcome of the larger SIOP/UKCCSG study to define the efficacy of this treatment regimen and make an effective comparison with other treatment strategies.
Whatever the eventual outcome of the current clinical trials the importance of studying these very young children cannot be overstated. Population based studies show that standard treatment approaches with neurosurgery and radiotherapy are rejected, while institutional based studies repeatedly show a poor quality of outcome. These issues are concentrating the minds of paediatric oncologists, radiotherapists, and neurosurgeons to undertake rapid evaluation of the role of chemotherapy and to define an effective multidisciplinary approach to brain tumour management. To this end there is a wide range of phase I and II studies within the United Kingdom to test novel cytotoxics in childhood brain tumours. It is likely that lessons learned in these patients will affect the development of novel treatment strategies for older children.
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